NeuClone Starts Trial For Ustekinumab Biosimilar
NeuLara Rival To Stelara Enters Phase I Clinical Trial
After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.
You may also be interested in...
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.